Does Cyclobenzaprine Make You Sleepy the Next Day?

Cyclobenzaprine frequently causes next-day drowsiness, and the effect can be more impairing than people realize. Somnolence is consistently the most commonly reported side effect in clinical trials, and driving-simulation research shows that the drug measurably impairs performance even when users feel fine behind the wheel. How much it affects you the next morning depends on the dose, the formulation, your age, and the time of day you take it.

Why Cyclobenzaprine Is So Sedating

Cyclobenzaprine is structurally almost identical to older tricyclic antidepressants, which are well known for making people drowsy. Researchers have long suspected that the sedation is not just an accidental byproduct of its muscle-relaxing action but comes from the drug blocking histamine receptors in the brain. A laboratory study confirmed this, showing that cyclobenzaprine binds with strong affinity to the H1 histamine receptor and blocks its activity in a non-competitive manner.¹ Histamine is one of the brain’s key wakefulness signals. When a drug blocks H1 receptors, the result is essentially the same drowsiness you get from a first-generation antihistamine like diphenhydramine (the active ingredient in many over-the-counter sleep aids). Because cyclobenzaprine crosses into the brain easily, the sedation can be pronounced.

This matters for next-day sleepiness because cyclobenzaprine has a long half-life, typically ranging from about 18 hours in younger adults up to considerably longer in older people. That means the drug is still circulating in your bloodstream the following morning at concentrations high enough to keep blocking histamine receptors well after you wake up.

How Common Next-Day Drowsiness Actually Is

In placebo-controlled trials of the standard immediate-release tablets, somnolence and dry mouth are consistently the most frequently reported side effects, and both are dose-related.² The higher the dose, the more likely you are to feel drowsy the following day. In studies of fibromyalgia patients taking higher daytime doses (up to 40 mg), about a third of patients reported daytime drowsiness.³ That is a meaningful chunk of users dealing with grogginess during hours when they need to function.

Even at lower doses, somnolence remains the most common adverse event across multiple pharmacokinetic studies comparing different formulations.⁴ The consistent finding across trials is that if you take cyclobenzaprine, next-day drowsiness is not a rare or unusual reaction. It is the expected experience for a sizable portion of users.

The Driving Simulation Evidence Is Unsettling

Perhaps the most concerning data on next-day effects comes from studies that put people behind the wheel of a driving simulator after taking cyclobenzaprine. In a crossover study comparing cyclobenzaprine to a placebo, subjects showed significant impairment on the primary measure of driving ability, a metric called standard deviation of lateral position that captures how much a driver weaves within their lane. Cyclobenzaprine users weaved significantly more than those on placebo, and most of the secondary driving and cognitive endpoints told the same story.⁵

The impairment did not end on the first day. Results extended into days two and three of the study period. Some subjects reached levels of lane-weaving that researchers associate with a blood alcohol concentration above 0.05 percent, which is the legal limit in many countries and approaching it in the United States.⁶

What makes this particularly alarming is the disconnect between how impaired people were and how impaired they felt. On day one, only about 10 percent of subjects taking cyclobenzaprine said they felt unsafe to drive. By day two, that number dropped to about 3 percent, even though their driving performance was still measurably impaired.⁵ In other words, the overwhelming majority of people on cyclobenzaprine thought they were fine to drive when the data said otherwise. This false sense of normalcy is the kind of side effect that doesn’t show up on a patient information sheet in a way that grabs your attention, but it has real consequences on the road.

Immediate-Release Versus Extended-Release Formulations

Cyclobenzaprine comes in two main formulations. The immediate-release (IR) version is typically prescribed as 5 mg or 10 mg tablets taken up to three times a day. The extended-release (ER) version delivers 15 mg or 30 mg once daily. You might assume the extended-release version, with its slower absorption, would cause less next-day drowsiness. The pharmacokinetic picture is more complicated than that.

In healthy young adults, the extended-release 30 mg tablet produced a smoother, single-peak concentration curve over 24 hours, with drug levels peaking at roughly six hours. The immediate-release version, taken three times daily, produced a series of peaks and troughs throughout the day, with its first peak hitting at about four hours.⁴ Total drug exposure over 24 hours was similar between the two formulations. The extended-release version avoids the sharp concentration spikes of the immediate-release form, which could theoretically reduce the intensity of drowsiness at any single moment. But the drug is still present at meaningful levels throughout the following morning either way.

In older adults, a similar pharmacokinetic comparison found that the extended-release version peaked later, at a median of about eight hours versus five hours for the first dose of immediate-release. Again, total systemic exposure was comparable between the two formulations, and somnolence was the most common side effect reported with both.⁷ The takeaway is that switching to the extended-release formulation does not eliminate next-day drowsiness. It may smooth out the highs and lows of sedation across the day, but the drug’s long half-life means it lingers regardless of how it was packaged.

Why Older Adults Face Greater Risk

Cyclobenzaprine clearance slows with age. The drug’s half-life extends as liver metabolism becomes less efficient, which means older adults carry higher drug concentrations for longer periods. In the elderly pharmacokinetic study mentioned above, somnolence remained the most commonly reported adverse event.⁷ Cyclobenzaprine appears on the Beers Criteria, a widely referenced list of medications that are potentially inappropriate for older adults, largely because of its anticholinergic and sedating properties. Falls, confusion, and impaired cognition are all concerns when an older person takes a drug with this profile and then gets out of bed the next morning still under its influence.

The practical issue goes beyond feeling groggy. Older adults who are drowsy are more likely to fall, and a fall in someone with reduced bone density can mean a hip fracture or worse. If you are over 65 and have been prescribed cyclobenzaprine, the next-day sedation is not just an inconvenience. It becomes a genuine safety issue.

How Cyclobenzaprine Compares to Other Muscle Relaxants

Not all muscle relaxants are equally sedating. A clinical review comparing commonly prescribed options noted that cyclobenzaprine and tizanidine are among the more sedating choices, with their drowsiness sometimes being reframed as a feature for patients whose muscle spasms keep them from sleeping. Other muscle relaxants, such as methocarbamol and metaxalone, are generally considered less sedating, though the evidence for their effectiveness is more limited.⁸

That said, the same review noted that dizziness and drowsiness are reported with all skeletal muscle relaxants to some degree. If next-day drowsiness is a serious concern for your daily routine, such as driving to work or operating equipment, it is worth having a specific conversation with your prescriber about which agent is least likely to affect your daytime function. Cyclobenzaprine is effective for short-term muscle spasm, but its sedation profile is heavier than several alternatives.

Dose Timing and Very Low Doses

One strategy that has shown some promise for reducing next-day drowsiness is taking a very low dose of cyclobenzaprine at bedtime rather than a standard dose during the day. In a study of fibromyalgia patients, a very low dose given at bedtime resulted in about 22 percent of patients reporting daytime drowsiness, compared to roughly 34 percent in a study using higher daytime doses.³ The logic is straightforward: a smaller dose means lower peak blood levels, and timing it at bedtime means the sedation works with your sleep schedule rather than fighting against your waking hours.

A newer sublingual formulation of cyclobenzaprine at a low dose (5.6 mg at bedtime) has been tested in large trials for fibromyalgia and was generally well tolerated, with somnolence rates of about 3 percent versus 1.3 percent for placebo.⁹ That is a much lower rate of next-day drowsiness than what is seen with the standard 10 mg tablets taken during the day. The sublingual route delivers the drug more quickly and at a lower total dose, which means it can promote sleep onset without leaving as much residual drug circulating the next morning.

These findings suggest that for patients who benefit from cyclobenzaprine but are bothered by daytime grogginess, the combination of lower doses and bedtime dosing can meaningfully reduce the problem, even if it does not eliminate it entirely.

Factors That Make Next-Day Drowsiness Worse

Several things can amplify cyclobenzaprine’s hangover effect beyond what the drug alone would cause. Alcohol is the obvious one: combining a central nervous system depressant with another one compounds the sedation in ways that are not merely additive. Other sedating medications, including benzodiazepines, opioids, antihistamines, and sleep aids, create the same layered sedation.

Liver function matters significantly. Cyclobenzaprine is metabolized primarily by the liver, and anyone with reduced liver function will clear the drug more slowly, meaning higher blood levels the next morning. This includes not just people with diagnosed liver disease but also those taking other medications that compete for the same metabolic pathways. The practical result is that some people will carry effective sedating concentrations of cyclobenzaprine far longer than the average half-life would predict.

Body composition, hydration status, and individual genetic variation in drug-metabolizing enzymes all play a role as well. Two people of the same age taking the same dose can have meaningfully different experiences the following morning. If you feel unusually groggy the day after your first dose, that is real information about how your body handles the drug, not something you should assume will go away after a few days.

The Gap Between Feeling Alert and Being Alert

The driving simulation findings deserve emphasis as their own practical point, because they reveal something that applies beyond just driving. The research showed that people on cyclobenzaprine perceived almost no impairment by the second day, while objective testing demonstrated that their cognitive and motor function was still compromised.⁶ This is not unique to cyclobenzaprine; many sedating medications produce a similar mismatch. But the magnitude here is striking, and it means that asking yourself “do I feel drowsy?” is not a reliable test of whether the drug is still affecting your abilities.

This has implications beyond the car. Operating power tools, making complex decisions at work, caring for young children, and any other task that requires quick reaction time or sustained attention can all be affected while you still feel subjectively fine. If the prescription label says to avoid driving or hazardous activities, it is not being overly cautious. The evidence suggests the warning is, if anything, underselling the risk because it relies on the patient to notice something that cyclobenzaprine specifically makes harder to notice.

When Sedation Is Actually the Point

It is worth acknowledging that for some patients, the sedating properties of cyclobenzaprine are a benefit rather than a bug. People with severe muscle spasms that prevent sleep sometimes find that the drowsiness helps them finally get rest, which in turn aids muscle recovery.⁸ The drug’s use in fibromyalgia research also leverages this connection between sleep improvement and pain reduction. A bedtime sublingual formulation was specifically designed to improve nonrestorative sleep, and the phase 3 trial showed significant improvements in pain and function alongside good tolerability.⁹

The distinction is context-dependent. If you take cyclobenzaprine at 10 PM and have nowhere to be until noon the next day, the residual drowsiness is manageable and may even feel pleasant as a lingering calm. If you take it and then need to drive to work at 7 AM, that same pharmacology becomes a liability. The drug itself does not change; what changes is whether the sedation aligns with or interferes with your schedule and responsibilities.